Skip to content
Disclosery

SUPERSTRING CAPITAL MANAGEMENT LP

Follow

13F filer, CIK 1931118, NEW YORK, NY

SUPERSTRING CAPITAL MANAGEMENT LP reported $101,502,599 across 35 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 53.57% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001931118-25-000010

Period
2025-09-30
Reported value
$102M
Holdings
35
Top 10 weight
53.57%
New
16
Sold out
17

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CDTXnew+68,463$6.56M
IMVTnew+341,348$5.5M
SMMTnew+197,253$4.08M
IQVnew+19,114$3.63M
REGNnew+6,401$3.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
COGTreduced-601,543-$8.64M
VERONA PHARMA PLCexited-68,982-$6.52M
TVTXreduced-222,847-$5.33M
NBIXexited-40,608-$5.1M
RAREexited-130,422-$4.74M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001931118-25-000010, largest first. % of portfolio is the value over $101,502,599, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 626,932 shares; 2024Q4: 403,630 shares; 2025Q1: 294,947 shares; 2025Q2: 134,895 shares; 2025Q3: 200,628 shares 200,628$6.8M6.7%+65,733Timeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 68,463 shares 68,463$6.56M6.46%newTimeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,348,546 shares; 2024Q4: 2,020,562 shares; 2025Q1: 1,357,153 shares; 2025Q2: 1,286,681 shares; 2025Q3: 789,646 shares 789,646$5.93M5.84%-497,035Timeline
89BIO INC89BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 595,203 shares; 2024Q4: 132,982 shares; 2025Q1: 109,156 shares; 2025Q2: 212,377 shares; 2025Q3: 384,652 shares 384,652$5.65M5.57%+172,275
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,447 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 341,348 shares 341,348$5.5M5.42%newTimeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 44,107 shares; 2025Q3: 40,893 shares 40,893$5.39M5.31%-3,214Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 910,865 shares; 2025Q1: 774,721 shares; 2025Q2: 962,951 shares; 2025Q3: 361,408 shares 361,408$5.19M5.11%-601,543Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 200,000 shares; 2024Q4: 508,338 shares; 2025Q1: 966,203 shares; 2025Q2: 1,115,379 shares; 2025Q3: 1,309,236 shares 1,309,236$4.67M4.6%+193,857Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 226,684 shares; 2024Q4: 262,141 shares; 2025Q1: 183,922 shares; 2025Q2: 96,766 shares; 2025Q3: 88,658 shares 88,658$4.6M4.54%-8,108Timeline
SMMTSUMMIT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 164,564 shares; 2025Q1: 132,019 shares; 2025Q2: not reported; 2025Q3: 197,253 shares 197,253$4.08M4.01%newTimeline
IQVIQVIA HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 19,114 shares 19,114$3.63M3.58%newTimeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 131,795 shares; 2024Q4: 822,293 shares; 2025Q1: 458,972 shares; 2025Q2: 1,060,764 shares; 2025Q3: 1,544,525 shares 1,544,525$3.61M3.56%+483,761Timeline
REGNREGENERON PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 6,401 shares 6,401$3.6M3.55%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 53,950 shares 53,950$3.27M3.22%newTimeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 51,270 shares 51,270$2.92M2.87%newTimeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 35,966 shares; 2025Q1: not reported; 2025Q2: 14,571 shares; 2025Q3: 19,786 shares 19,786$2.85M2.81%+5,215Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 189,699 shares; 2025Q3: 175,902 shares 175,902$2.78M2.74%-13,797Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 188,080 shares 188,080$2.39M2.36%newTimeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 50,407 shares 50,407$2.38M2.34%newTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 111,605 shares; 2024Q4: 111,605 shares; 2025Q1: 111,605 shares; 2025Q2: 111,605 shares; 2025Q3: 96,665 shares 96,665$2.15M2.11%-14,940Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 33,175 shares 33,175$1.94M1.91%newTimeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 50,746 shares; 2025Q2: 79,058 shares; 2025Q3: 119,286 shares 119,286$1.87M1.84%+40,228Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 301,206 shares; 2025Q1: 423,632 shares; 2025Q2: 87,912 shares; 2025Q3: 87,912 shares 87,912$1.75M1.73%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 360,000 shares; 2025Q1: 360,000 shares; 2025Q2: 360,000 shares; 2025Q3: 360,000 shares 360,000$1.57M1.54%0Timeline
KROSKEROS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 95,083 shares 95,083$1.5M1.48%newTimeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 39,521 shares 39,521$1.47M1.45%newTimeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 68,892 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 20,358 shares 20,358$1.35M1.33%newTimeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 237,487 shares; 2025Q2: 276,474 shares; 2025Q3: 53,627 shares 53,627$1.28M1.26%-222,847Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 949,522 shares; 2024Q4: 1,580,745 shares; 2025Q1: 819,194 shares; 2025Q2: 344,922 shares; 2025Q3: 89,346 shares 89,346$1.07M1.06%-255,576Timeline
RAPTRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 26,034 shares; 2025Q3: 34,449 shares 34,449$888K0.88%+8,415Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 150,312 shares 150,312$858K0.85%newTimeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 25,401 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 57,644 shares 57,644$729K0.72%newTimeline
NBPNOVABRIDGE BIOSCIENCESQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 139,886 shares 139,886$529K0.52%newTimeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 83,554 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 250,000 shares; 2025Q3: 250,000 shares 250,000$505K0.5%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 462,963 shares; 2025Q1: 462,963 shares; 2025Q2: 462,963 shares; 2025Q3: 462,963 shares 462,963$231K0.23%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERONA PHARMA PLCVERONA PHARMA PLC68,982$6.52Mshares
NBIXNEUROCRINE BIOSCIENCES INC40,608$5.1Mshares
RAREULTRAGENYX PHARMACEUTICAL IN130,422$4.74Mshares
SLNOSOLENO THERAPEUTICS INC50,000$4.19Mput
IONSIONIS PHARMACEUTICALS INC98,267$3.88Mshares
SLNOSOLENO THERAPEUTICS INC33,691$2.82Mshares
CYTKCYTOKINETICS INC61,103$2.02Mshares
UTHRUNITED THERAPEUTICS CORP DEL4,874$1.4Mshares
RNAMAVIDITY BIOSCIENCES INC47,037$1.34Mshares
LQDALIQUIDIA CORPORATION71,071$886Kshares
MLTXMOONLAKE IMMUNOTHERAPEUTICS17,623$832Kshares
OCULOCULAR THERAPEUTIX INC88,980$826Kshares
RCKTROCKET PHARMACEUTICALS INC214,412$525Kshares
WVEWAVE LIFE SCIENCES LTD70,242$457Kshares
KYTXKYVERNA THERAPEUTICS INC142,542$438Kshares
SYSO YOUNG INTERNATIONAL INC72,936$226Kshares
LAKESHORE BIOPHARMA CO LTDLAKESHORE BIOPHARMA CO LTD30,792$31.4Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001931118-25-000010 base2025-11-14acceptance time not in the bulk data set